同步放化疗对非小细胞肺癌患者Fas水平的影响

The level change of serum soluble Fas for non-small cell lung cancer patients with concurrent radiochemotherapy

目的用酶联免疫吸附试验研究非小细胞肺癌患者同步放化疗对血清可溶性Fas的影响及其与预后的关系。方法对60例患者比较治疗前、治疗后1个月血清Fas水平变化，并设正常对照组。比较治疗有效组（完全缓解＋部分缓解，50例）与无效组（无变化＋进展，10例）治疗前Fas水平变化。以2年生存为观察指标，观察血清Fas水平对生存时间的影响。结果非小细胞肺癌患者治疗前血清Fas水平明显高于正常对照组（8．55±0．63）ng／L和（6．03±0．55）ng／L（t=18．63，P〈0．01），治疗后1个月明显低于治疗前（7．24±0．52）ng／L和（8．55±0．63）ng／L（t=12．44，P〈0．01）。治疗有效组疗前血清Fas水平明显低于无效组的（8．02±0．43）ng／L和（8．97±0．42）ng／L（t=8．67，P〈0．01）。生存满2年者（26例）治疗前Fas水平明显低于生存不足2年者（34例）（t=645．88，P〈0．05）。结论同步放化疗可降低非小细胞肺癌患者血清可溶性Fas水平，治疗前后Fas水平变化有可能成为判断非小细胞肺癌患者预后的观察指标。

Objective Study on the change of serum soluble Fas （sFas） level and prognostic relation for non-small cell lung cancer （NSCLC） patients with concurrent radio-chemotherapy using enzyme linked immunosorbent assays（ELISA）. Methods Sixty patients were obtained. The sFas level were compared before treatment with one month after treatment, and healthy donors were used as controls level of sFas. The sFas level of before treatment were compared treatment efficiency patients （complete remission and partial remission, 50 patients） and treatment inefficiency patients（no change and progressive disease, 10 patients）. The correlation was analyzed between 2-year survival NSCLC patients and their sFas level. Results The sFas level before treatment in NSCLC patients was obviously higher than healthy controls （8.55±0.63） ng/L and （6.03 ± 0.55） ng/L; （t = 18.63, P 〈 0.01 ）, with 1 inonth after treatment obviously lower than before treatment in NSCLC patients （7.24 ± 0.52） ng/L and （8.55 ± 0.63） ng/L; （t = 12.44, P 〈 0.01）. The sFas level of before treatment was treatment efficiency patients obviously lower than treatment ineffeetived patients （8.02 ± 0.43） ng/ L and （8.97 ± 0.42） ng/L; （ t = 8.67, P 〈 0.01 ）, with 2-year survival patients obviously（26 patients） lower than shortage 2-year survival patients （34 patients） （ t = 645.88, P 〈 0.05 ）. Conclusions Concurrent radiochemotherapy can reduce sFas level in NSCLC patients, the changes of sFas level before and after treatment may provide worth prognostic for NSCLC patients.